Measurement of visual acuity (ETDRS lines) (median (SD)) and gain in visual acuity (Snellen lines) after intravitreal injection of 4 mg, 8 mg, or 25 mg triamcinolone acetonide
| Time | No | Visual acuity | LogMAR units | p Value | Gain in visual acuity (Snellen lines) |
|---|---|---|---|---|---|
| The dosage was measured before filtration of the triamcinolone acetonide crystals. Peak time was defined as the time, at which visual acuity started to decline again. p Value, difference to the baseline value in each study group; NS, statistically not significant. | |||||
| 2 mg study group | |||||
| Pre-injection | 8 | 0.18 (0.16) | 0.91 (0.39) | ||
| 1 week | 6 | 0.19 (0.17) | 0.89 (0.44) | 0.92 (NS) | 0.50 (2.37) |
| 1 month | 7 | 0.23 (0.21) | 0.83 (0.49) | 0.22 (NS) | 0.64 (2.93) |
| 3 months | 8 | 0.22 (0.21) | 0.80 (0.39) | 0.20 (NS) | 0.39 (2.26) |
| 6 months | 6 | 0.21 (0.22) | 0.86 (0.44) | 0.58 (NS) | 0.42 (2.06) |
| 9 months | 3 | 0.23 (0.23) | 0.77 (0.40) | 0.20 (NS) | 0.83 (0.76) |
| Max during follow up | 8 | 0.23 (0.19) | 0.80 (0.39) | 0.09 (NS) | 1.13 (2.42) |
| At end of follow up | 8 | 0.19 (0.16) | 0.85 (0.38) | 0.57 (NS) | 0.63 (2.00) |
| Maximal gain | 8 | 0.05 (0.07) | −0.10 (0.10) | 1.13 (2.42) | |
| Duration of effect (months) | 8 | 0.92 (1.25) | |||
| Gain ⩾2 Snellen lines | 3/8 (38%) | ||||
| 5 mg study group | |||||
| Pre injection | 10 | 0.18 (0.23) | 1.00 (0.53) | ||
| 1 week | 4 | 0.08 (0.04) | 1.14 (0.26) | 0.48 (NS) | −0.50 (5.68) |
| 1 month | 8 | 0.24 (0.25) | 0.79 (0.43) | 0.21 (NS) | 0.88 (1.36) |
| 3 months | 8 | 0.13 (0.09) | 0.99 (0.37) | 0.34 (NS) | 1.13 (1.81) |
| 6 months | 6 | 0.30 (0.28) | 0.72 (0.46) | 0.15 (NS) | 1.33 (2.25) |
| 9 months | 4 | 0.11 (0.10) | 1.11 (0.40) | 0.12 (NS) | 2.50 (2.08) |
| Max during follow up | 10 | 0.23 (0.23) | 0.82 (0.41) | 0.012 | 1.90 (1.73) |
| At end of follow up | 10 | 0.21 (0.23) | 0.86 (0.42) | 0.076 (NS) | 1.20 (1.99) |
| Maximal gain | 10 | 0.05 (0.05) | −0.18 (0.23) | 2.09 (1.76) | |
| Duration of effect (months) | 10 | 2.30 (2.63) | |||
| Gain ⩾2 lines | 5/10 (50%) | ||||
| 13 mg study group | |||||
| Pre injection | 9 | 0.15 (0.13) | 1.11 (0.61) | ||
| 1 week | 6 | 0.23 (0.13) | 0.71 (0.30) | 0.014 | 4.80 (4.49) |
| 1 month | 8 | 0.22 (0.16) | 0.79 (0.39) | 0.011 | 3.50 (4.14) |
| 3 months | 9 | 0.26 (0.18) | 0.71 (0.39) | 0.019 | 3.63 (4.75) |
| 6 months | 8 | 0.26 (0.12) | 0.65 (0.27) | 0.030 | 3.63 (4.44) |
| 9 onths | 2 | 0.25 (0.21) | 0.70 (0.43) | 0.037 | 4.50 (4.95) |
| Max during follow up | 9 | 0.30 (0.18) | 0.66 (0.40) | 0.002 | 4.11 (4.37) |
| At end of follow up | 9 | 0.24 (0.13) | 0.71 (0.36) | 0.023 | 3.56 (4.75) |
| Maximal gain | 9 | 0.15 (0.10) | −0.46 (0.53) | 4.11 (4.37) | |
| Duration of effect 9 (months) | 4.33 (3.91) | ||||
| Gain ⩾2 lines | 7/9 (78%) | ||||